期刊
BIOMARKERS IN MEDICINE
卷 13, 期 9, 页码 785-799出版社
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2018-0492
关键词
biomarkers; coronary artery disease; diagnosis; heart failure; placenta growth factor; PlGF; prognosis; sFlt-1; soluble fms-like tyrosine kinase receptor-1
Coronary heart disease (CHD) and heart failure (HF) produce significant morbidity/mortality but identifying new biomarkers could help in the management of each. In this article, we summarize the molecular regulation and biomarker potential of PIGF and sFlt-1 in CHD and HF. PlGF is elevated during ischemia and some studies have shown PlGF, sFlt-1 or PlGF: sFlt-1 ratio, when used in combination with standard biomarkers, strengthens predictions of outcomes. sFlt-1 and PlGF are elevated in HF with sFlt-1 as a stronger predictor of outcomes. Although promising, we discuss additional study criteria needed to confirm the clinical usefulness of PlGF or sFlt-1 in the detection and management of CHD or HF.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据